Skip to main content
Log in

Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; a comparative study using different protocols

  • Original article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) can identify viable myocardium in patients with coronary artery disease. Recently, FDG imaging with single-photon emission tomography (SPET) and 511-keV collimators has been described. To obtain optimal image quality in all patients, cardiac FDG studies should be performed during hyperinsulinaemic glucose clamping. It has been suggested that FDG imaging after the administration of a nicotinic acid derivative may yield comparable image quality to clamping. We studied eight patients and compared the image quality of cardiac FDG SPET studies after oral glucose loading, after administration of a nicotinic acid derivative (acipimox, 250 mg orally) and during hyperinsulinaemic glucose clamping. The image quality was expressed as the myocardial to blood pool (M/B) activity ratio, which is used as a measure of the target-to-background ratio The M/B ratios were comparable after clamping and acipimox (2.8±0.8 vs 2.9±0.7), whereas the M/B ratio was lower after oral glucose loading (2.2±0.3,P<0.05 vs clamp and acipimox). To determine the clearance of FDG from the plasma, blood samples were drawn at fixed time intervals and the FDG activity was measured in a gamma well counter. The FDG clearance was significantly lower after oral glucose loading (T 1/2 oral load=16.2±5.7 min) as compared with clamping (T 1/2 clamp=8.1±3.1 min) and acipimox (T 1/2 acipimox=10.7±4.0 min, NS vs clamp,P<0.05 vs oral load). It may be concluded that FDG SPET imaging after acipimox administration yields image quality and clearance rates comparable to those obtained during clamping. FDG SPET in combination with acipimox may useful in clinical routine for the assessment of myocardial viability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schwaiger M, Hicks R. The clinical role of metabolic imaging of the heart by positron emission tomography.J Nucl Med 1991; 32: 565–578.

    Google Scholar 

  2. Schelbert HR. Metabolic imaging to assess myocardial viability.J Nucl Med 1994; 35 (Suppl): 8S–14S.

    Google Scholar 

  3. Bax JJ, Visser FC, van Lingen A, et al. Feasibility of assessing regional myocardial uptake of18F-fluorodeoxyglucose using single photo emission computed tomography.Eur Heart J 1993; 14: 1675–1682.

    Google Scholar 

  4. Bax JJ, Visser FC, van Lingen A, et al. Relation between myocardial uptake of thallium-201 chloride and F18-fluorodeoxyglucose imaged with SPECT in normal volunteers.Eur J Nucl Med 1995; 22: 56–60.

    Google Scholar 

  5. Martin WH, Delbeke D, Patton JA, et al. FDG-SPECT: correlation with FDG-PET.J Nucl Med 1995; 36: 988–995.

    Google Scholar 

  6. Burt RW, Perkins OW, Oppenheim BE, et al. Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for the detection of myocardial viability.J Nucl Med 1995; 36: 176–179.

    Google Scholar 

  7. Bax JJ, Cornel JH, Visser FC, et al. Quantitative analysis of FDG and Tl-201 SPECT for the prediction of functional outcome after revascularization [abstract].J Nucl Med 1995; 36: 36P.

  8. Maddahi J, Schelbert H, Brunken R, Di Carli M. Role of thallium-201 and PET imaging in evaluation of myocardial viability and management of patients with coronary artery disease and left ventricular dysfunction.J Nucl Med 1994; 35: 707–715.

    Google Scholar 

  9. Gropler RJ. Methodology governing the assessment of myocardial glucose metabolism by positron emission tomography and fluorine 18-labeled fluorodeoxyglucose.J Nucl Cardiol 1994; 1: S4-S14.

    Google Scholar 

  10. Knuuti MJ, Nuutili P, Ruotsalainen U, et al. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography.J Nucl Med 1992; 1255–1262.

  11. Knuuti MJ, Yki-Järvinen H, Voipio-Pulkki LM, et al. Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative.J Nucl Med 1994; 35: 989–998.

    Google Scholar 

  12. Melin JA, Becker LC. Quantitative relationship between global left ventricular thallium uptake and blood flow: effects of propranolol, ouabain, dipyridamole and coronary artery occlusion.J Nucl Med 1986; 27: 641–652.

    Google Scholar 

  13. Phelps ME, Hoffman EJ, Selin C, et al. Investigation of [18F]2-fluoro-2-deoxyglucose for the measure of myocardial glucose metabolism.J Nucl Med 1978; 19: 1311–1319.

    Google Scholar 

  14. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan C, Wolf AP. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of18F-2-deoxy-2-fluoro-D-glucose.J Nucl Med 1978; 19: 1154–1161.

    Google Scholar 

  15. Van Lingen A, Huijgens PC, Visser VC, et al. Performance characteristics of a 511-keV collimator for imaging positron emitters with a standard gamma-camera.Eur J Nucl Med 1992; 19: 315–321.

    Google Scholar 

  16. Lee KS, vom Dahl J, Hicks RJ, Schwaiger M. Relationship between blood glucose levels and F-18 fluorodeoxyglucose image quality in cardiac PET FDG studies [abstract].J Am Coll Cardiol 1991; 17: 120A.

  17. Vom Dahl J, Hermann WH, Hicks RJ, et al. Myocardial glucose uptake in patients with insulin-dependent diabetes mellitus assessed by positron emission tomography.Circulation 1993; 395–404.

  18. Ohtake T, Yokoyama I, Watanabe T, et al. Myocardial glucose metabolism in noninsulin-dependent diabetes mellitus patients evaluated by FDG-PET.J Nucl Med 1995; 36: 456–463.

    Google Scholar 

  19. Nuutili P, Koivisto VA, Knuuti J, et al. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo.J Clin Invest 1992; 89: 1767–1774.

    Google Scholar 

  20. Musatti L, Maggi E, Moro E, et al. Bioavailability and pharmacokinetics of Acipimox, a new antilipolytic and hypolipidaemic agent.J Int Med Res 1981; 381–386.

  21. Huitink JM, Visser FC, van Leeuwen GJ, et al. Influence of high and low plasma insulin levels on the uptake of18F-FDG in myocardium and femoral muscle as assessed by planar imaging.Eur J Nucl Med 1995; 22: 1141–1148.

    Google Scholar 

  22. Bax JJ, Visser FC, Blanksma PK et al. Comparison of myocardial uptake of18F-fluorodeoxyglucose imaged with positron emission tomography and single photon emission computed tomography in dyssynergic myocardium.J Nucl Med 1996; in press.

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bax, J.J., Veening, M.A., Visser, F.C. et al. Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; a comparative study using different protocols. Eur J Nucl Med 24, 35–41 (1997). https://doi.org/10.1007/BF01728306

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01728306

Key words

Navigation